Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence
Authors Giovanni Vanni Frajese, Flavio Pozzi, Gaetano Frajese
Published 15 January 2007 Volume 2006:1(4) Pages 439—449
Giovanni Vanni Frajese, Flavio Pozzi, Gaetano Frajese
Department of Internal Medicine, Chair of Endocrinology - University of Rome Tor Vergata, Rome, Italy
Abstract: Prevalence and severity of erectile dysfunction (ED) increase with aging and are often associated with illnesses, like diabetes mellitus, heart disease, and hypertension, pathologically characterized by endothelial dysfunction and whose prevalence increases with age. The assumption that ED is mainly a neurovascular disease is supported by the evidence that specific phosphodiesterase type 5 (PDE5) inhibition produces an efficient erection in a wide range of ages and conditions. The availability of specific PDE5 inhibitors has enabled the development of effective treatment strategies, in this contest, tadalafil may be considered as the least “typical” PDE5 inhibitor. In clinical trials, tadalafil significantly enhanced, in patients of different ages, all efficacy outcomes across disease etiologies and severities. With an effectiveness lasting up to 36h, tadalafil allows patients to choose when to have sexual activities without the need to time it, showing positive feedback in terms of quality of life related to the treatment. Headache and dyspepsia were the most frequent side-effects of tadalafil, followed by back pain, nasal congestion, myalgia, and flushing, but the impact that long time action could have on effectiveness and safety is not yet entirely defined. The aim of this article is to critically review the available evidence from the tadalafil clinical research program and give the physician a rational approach for intervention in the treatment of ED and related diseases.
Keywords: tadalafil, PDE5 inhibitors, erectile dysfunction, aging, sexual behavior